Literature DB >> 22382989

Pharmacokinetic and safety of raltegravir in pregnancy.

Leonardo Croci, Michele Trezzi, Maria Pia Allegri, Tiziana Carli, Silvia Chigiotti, Maria Piera Riccardi, Barbara Ricciardi, Mario Toti, Cesira Nencioni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22382989     DOI： 10.1007/s00228-012-1250-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

1.  High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.

Authors:  Denise A McKeown; Melanie Rosenvinge; Sheila Donaghy; Mike Sharland; David W Holt; Ian Cormack; Phillip Hay; S Tariq Sadiq
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

2.  Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.

Authors:  Carmela Pinnetti; Silvia Baroncelli; Paola Villani; Massimo Fantoni; Valerio Tozzi; Andrea De Luca; Roberto Cauda; Gianfranco Anzidei; Maria Cusato; Mario Regazzi; Marco Floridia; Enrica Tamburrini
Journal:  J Antimicrob Chemother       Date:  2010-07-14       Impact factor: 5.790

3.  U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Authors:  Lynne M Mofenson
Journal:  MMWR Recomm Rep       Date:  2002-11-22

4.  Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation.

Authors:  M Sun; J Kingdom; D Baczyk; S J Lye; S G Matthews; W Gibb
Journal:  Placenta       Date:  2005-09-06       Impact factor: 3.481

5.  Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

Authors:  Denise Jaworsky; Courtney Thompson; Mark H Yudin; Ari Bitnun; Jason Brophy; Lindy Samson; Tony Antoniou; Mona R Loutfy
Journal:  Antivir Ther       Date:  2010

6.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

Authors:  Vincenzo Summa; Alessia Petrocchi; Fabio Bonelli; Benedetta Crescenzi; Monica Donghi; Marco Ferrara; Fabrizio Fiore; Cristina Gardelli; Odalys Gonzalez Paz; Daria J Hazuda; Philip Jones; Olaf Kinzel; Ralph Laufer; Edith Monteagudo; Ester Muraglia; Emanuela Nizi; Federica Orvieto; Paola Pace; Giovanna Pescatore; Rita Scarpelli; Kara Stillmock; Marc V Witmer; Michael Rowley
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

7.  Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

Authors:  Massimiliano Fabbiani; Simona Di Giambenedetto; Laura Bracciale; Alessandra Bacarelli; Enzo Ragazzoni; Roberto Cauda; Pierluigi Navarra; Andrea De Luca
Journal:  J Antimicrob Chemother       Date:  2009-04-27       Impact factor: 5.790

8.  Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.

Authors:  Kelem Kassahun; Ian McIntosh; Donghui Cui; David Hreniuk; Shelia Merschman; Kenneth Lasseter; Neal Azrolan; Marian Iwamoto; John A Wagner; Larissa A Wenning
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922
  8 in total
  7 in total

1.  Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.

Authors:  Bassam H Rimawi; Erica Johnson; Augustine Rajakumar; Sijia Tao; Yong Jiang; Scott Gillespie; Raymond F Schinazi; Mark Mirochnick; Martina L Badell; Rana Chakraborty
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Raltegravir pharmacokinetics during pregnancy.

Authors:  D Heather Watts; Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Tim R Cressey; Francesca Aweeka; Patty Lizak; Regis Kreitchmann; Sandra K Burchett; David E Shapiro; Elizabeth Hawkins; Elizabeth Smith; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-01       Impact factor: 3.731

3.  Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.

Authors:  Cécile Vinot; Jean-Marc Tréluyer; Carole Giraud; Laurent Gavard; Gilles Peytavin; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 4.  Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.

Authors:  Shelley A McCormack; Brookie M Best
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

5.  Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women.

Authors:  Diego M Cecchini; Marina G Martinez; Laura M Morganti; Claudia G Rodriguez
Journal:  Infect Dis Rep       Date:  2017-06-14

6.  A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomes.

Authors:  I Boucoiran; K Tulloch; N Pick; F Kakkar; J van Schalkwyk; D Money; M Boucher
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 May-Jun       Impact factor: 2.471

7.  Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.

Authors:  Blanca Miriam Torres-Mendoza; Damharis Elizabeth Coronado-Medina; Belinda Claudia Gómez-Meda; Eduardo Vázquez-Valls; Ana Lourdes Zamora-Perez; María de Lourdes Lemus-Varela; Guillermo Moisés Zúñiga-González
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.